Best of ASCO - 2014 Annual Meeting

 

Welcome

Mesothelioma

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
PBRM1 genomic alterations in mesothelioma: Potential predictor of immunotherapy efficacy.

Jeffrey S. Ross

8562

A real-world experience of nivolumab in advanced malignant mesothelioma (MM).

Hussein Hamad

8569

Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).

Nick Pavlakis

8568

CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma.

Dean Anthony Fennell

TPS8586

DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.

Anna K. Nowak

8503

Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma.

Vasiliki Panou

8564

Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes.

Paul Markowski

e20555

Impact of different risk factors on survival of malignant pleural mesothelioma.

Elisabeth Morin

e20561

Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.

Virginie Westeel

8505

Inherited predisposition to malignant mesothelioma (MM) due to mutations in DNA repair genes.

Raffit Hassan

8504

Long-term survival following trimodality therapy vs. medical management of malignant pleural mesothelioma.

Frédéric Larose

8560

Long-term survival outcomes of a placebo-controlled phase 3 trial with NGR-hTNF in combination with best investigator choice in relapsed malignant pleural mesothelioma (MPM).

Vanesa Gregorc

8567

Neoadjuvant versus adjuvant chemotherapy for resectable malignant pleural mesothelioma: An analysis of the National Cancer Database.

Fernando Espinoza-Mercado

e20556

NTRK and ALK rearrangements in mesothelioma and lung carcinoid.

Geoffrey David Peters

e20558

Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN Solid Tumor.

Raffit Hassan

8563

Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.

Marjorie Glass Zauderer

8515

Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).

Arpita Desai

8565

Radiosensitization and micro CT imaging of multifunctional gold nanoparticles in lung adenocarcinoma A549 cell: An in vivo animal study.

Tao Li

e20557

SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma.

Anne S. Tsao

8514

The TCGA malignant pleural mesothelioma (MPM) project: VISTA expression and delineation of a novel clinical-molecular subtype of MPM.

Marc Ladanyi

8516

Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.

Sanjay Popat

8566

Uncommon ALK fusion partners in advanced ALK-positive non-small-cell lung cancer.

Jin Kang

8561